Prevention and treatment of alzheimer's disease
AssigneeLars Lannfelt
InventorsLars Lannfelt, Camilla Nilsberth, Anita Westlind-Danielsson, Jan Naslund
Life of this patent
Estimating the term…
Abstract
The present invention relates to prevention and treatment of Alzheimer's disease (AD). More specifically, the invention relates to use of a non-wild type protofibril or compound(s) with protofibril forming activity for active immunization in the purpose of treating or preventing AD. The invention further relates to a peptide, Aβ-Arc, with high protofibril forming activity as well as several applications thereof, such as antibodies against said peptide for passive immunization against AD.
Claims21
Use of a non-wild type protofibril or compound(s) with protofibril forming ability for immunisation for prevention or treatment of Alzheimer's disease (AD).
Use according to any of the above claims, wherein said profibril or compound(s) with protofibril forming ability is used in combination with Aβ peptides having mutations.
A peptide Aβ-Arc having the amino acid sequence disclosed In SEQ ID NO 1 comprising a glycine at position 22 instead of glutamic acid compared to wild type Aβ peptide.
Transgenic non-human animal comprising a vector comprising the entire APP gene corresponding to NCBI database, accession no XM—009710, comprising the Arctic mutatation, i.e. nucleotide no. 2225 i mutated from A to G. leading to an amino acid substitution from Glutamic acid to Glycine.
Method for prevention or treatment of AD, comprising the step:
- decreasing the formation of Aβ protofibrils and/or lower meric forms thereof in a subject having, or suspected of having, AD.
Dependencies are inferred from the claim text.